A

fter Pfizer deferred hefty price hikes under pressure from President Trump, a lawmaker is asking the company and the administration to explain the details of any agreements that may have been reached as part of the sudden about-face.

Specifically, Sen. Ron Wyden (D-Ore.) wants to know if Pfizer (PFE) received any preferential treatment; what, if any, steps must be taken by the government for Pfizer to further delay price hikes; explain how the administration avoided interfering with any contracts Pfizer has with Medicare Part D plans; and whether the administration plans to approach other drug makers, among other things.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy